Carbamazepine

Generic Name: Carbamazepine

Brand Names: Carbatrol, Carnexiv, Epitol, Equetro, Tegretol

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₂N_₂O

CAS Number: 298-46-4

Unique Ingredient Identifier: 33CM23913M

Background: Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.

Indication: Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder. Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.

Associated Conditions: Acute Mania, Alcohol Withdrawal Syndrome, Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Mixed manic depressive episode, Pain, Partial Seizures With Secondary Generalization, Restless Legs Syndrome (RLS)

Clinical Trials

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Emraclidine
Drug: Itraconazole
Drug: Carbamazepine
Drug: Metformin

First Posted Date: 2023-07-28

Last Posted Date: 2024-04-02

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 60

Registration Number: NCT05965219

Locations: 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States

A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Itraconazole
Drug: Gemfibrozil
Drug: Carbamazepine

First Posted Date: 2023-07-06

Last Posted Date: 2023-10-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 47

Registration Number: NCT05932303

Locations: 🇨🇦
Local Institution - 0001, Québec, CA, Canada

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3537982
Drug: Itraconazole
Drug: Carbamazepine

First Posted Date: 2023-05-16

Last Posted Date: 2024-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT05860933

Locations: 🇺🇸
ICON Early Development Services, Salt Lake City, Utah, United States

A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: ALG-097558
Drug: Placebo
Drug: ALG-097558 in solution formulation
Drug: Carbamazepine
Drug: Midazolam
Drug: ALG-097558 in tablet formulation
Drug: Itraconazole

First Posted Date: 2023-05-03

Last Posted Date: 2025-04-08

Lead Sponsor: Aligos Therapeutics

Target Recruit Count: 90

Registration Number: NCT05840952

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Darigabat
Drug: Carbamazepine

First Posted Date: 2023-04-21

Last Posted Date: 2023-08-03

Lead Sponsor: Cerevel Therapeutics, LLC

Target Recruit Count: 13

Registration Number: NCT05824143

Locations: 🇺🇸
Orlando, Florida, Orlando, Florida, United States

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

Phase 4

Recruiting

Conditions: Drug Resistant Epilepsy

Interventions: Drug: Valproic acid
Drug: Lamotrigine
Drug: Carbamazepin
Drug: Clobazam
Drug: Phenytoin
Drug: Oxcarbazepine

First Posted Date: 2023-01-26

Last Posted Date: 2023-01-26

Lead Sponsor: Dr Cipto Mangunkusumo General Hospital

Target Recruit Count: 100

Registration Number: NCT05697614

Locations: 🇮🇩
Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia
🇮🇩
Harapan Kita Hospital, Jakarta, Indonesia
🇮🇩
Fatmawati Hospital, Jakarta, Indonesia